Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC
2.
A Win for Molecularly Guided Therapy for Cancer of Unknown Primary
3.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
4.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
5.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
1.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
2.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
3.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
4.
Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies
5.
How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge